What is the recommended bedtime dosing schedule of chlorpromazine (Thorazine) for an adult with psychosis?

Chlorpromazine (Thorazine) Once-Daily Bedtime Dosing for Psychosis

For adults with psychosis, chlorpromazine can be administered as a single bedtime dose starting at 25-50 mg, with gradual titration up to 200-800 mg at bedtime based on symptom control and tolerability. 1

Dosing Strategy

Starting Dose

• Initial bedtime dose: 25-50 mg orally 1
• Lower doses (25 mg) are preferred for elderly or debilitated patients 1
• Increase dosage gradually until symptoms are controlled 1

Titration Schedule

• Increase by increments of the initial dose every 5-7 days based on therapeutic response and side effects 2
• Target therapeutic range: 200-800 mg daily at bedtime 1
• Daily dosage of 200 mg is typical for maintenance 1
• Some discharged psychiatric patients may require up to 800 mg daily 1

Evidence for Once-Daily Bedtime Dosing

Research demonstrates that a single 400-800 mg dose of chlorpromazine at bedtime produces steady-state plasma levels equal to or better than multiple daily doses 3. A study of 25 patients with chronic schizophrenia showed that consolidating all psychotropics to nighttime dosing was feasible, with 74% of patients successfully maintained on this regimen 4. Patients favored the nighttime regimen primarily because it was less complicated 4.

Therapeutic Monitoring

Target Plasma Levels

• Optimal therapeutic range: 50-300 ng/mL 3
• This level is typically achieved with doses of 400-800 mg/day 3
• Doses below 400 mg/day may fail to achieve therapeutic plasma levels 3

Timeline for Response

• Maximum improvement may not be seen for weeks to months 1
• Continue optimum dosage for 2 weeks before adjusting 1
• After symptom control, gradually reduce to the lowest effective maintenance level 1

Critical Safety Considerations

Bedtime Dosing Advantages

• Minimizes daytime sedation and functional impairment
• Improves medication adherence through simplified regimen 4
• Leverages sedative properties to improve sleep quality 5

Key Monitoring Parameters

• Orthostatic hypotension: Keep patient lying down for at least 30 minutes after first doses 1
• Morning sedation: Most common adverse effect with bedtime dosing; address by dose reduction 4
• Extrapyramidal symptoms: Monitor closely, particularly at higher doses
• Complete blood count: Monitor frequently in first months due to risk of leukopenia/neutropenia 1

Important Drug Interactions

• Trihexyphenidyl decreases plasma chlorpromazine by mean of 44.7% 3 - avoid concurrent use or increase chlorpromazine dose accordingly
• Lithium may interfere with achieving therapeutic chlorpromazine levels 3
• Reduces effectiveness of oral anticoagulants 1

Special Populations

Elderly Patients

• Start with lower doses (12.5-25 mg at bedtime) 1
• More susceptible to hypotension and neuromuscular reactions 1
• Increase dosage more gradually 1
• Monitor closely for falls due to orthostatic hypotension

First-Episode Psychosis

While chlorpromazine is not a first-line agent for first-episode psychosis (atypical antipsychotics are preferred 6, 7), if used, employ approximately one-third lower doses than standard 8.

Clinical Pitfalls to Avoid

1. Do not use chlorpromazine as first-line therapy - atypical antipsychotics are preferred due to better tolerability 2, 6, 7
2. Avoid rapid dose escalation - increases risk of hypotension and extrapyramidal symptoms
3. Do not combine with anticholinergics (like trihexyphenidyl) as they significantly reduce chlorpromazine plasma levels 3
4. Monitor for morning sedation - the primary complaint with bedtime dosing that requires dose adjustment 4
5. Ensure adequate trial duration - at least 4-6 weeks at therapeutic dose before declaring treatment failure 9

When Chlorpromazine is Appropriate

Chlorpromazine should be considered second-line therapy after atypical antipsychotics have failed or are not tolerated 2. It remains useful for:

• Severe agitation requiring sedation 10, 11
• Refractory insomnia in psychotic patients 11
• Palliative care settings for delirium management 10, 11
• Cost-constrained settings where atypical antipsychotics are unavailable 7